Word

ELASMOGEN

Status

Pending

Status Code

686

Status Date

Tuesday, September 3, 2024

Serial Number

79379491

Mark Type

3

Filing Date

Wednesday, April 19, 2023

Published for Opposition

Tuesday, September 3, 2024

Trademark Owner History

Elasmogen Ltd - Owner At Publication

Classifications

5 Pharmaceutical preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations agents, and substances for medical purposes; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; diagnostic reagents for medical use; DNA, antibodies and proteins for medical diagnosis purposes; DNA and antibodies and proteins that stimulate cells for medical use; DNA, antibodies and proteins for therapeutic use for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations for medical purposes; reagents for medical use

44 Medical services; medical advisory services relating to the treatment, relief and prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; preparation and provision of medical reports to patients and medical professionals; preparation and provision of medical information in the form of reports on pharmaceuticals, advanced therapy medicinal products, and therapeutic antibodies to patients and medical professionals; consultancy, advice and information in the field of healthcare, pharmaceuticals and advanced therapy medicinal products

42 Medical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological research, clinical research and medical research; providing scientific information about the results of clinical trials for pharmaceutical products; research services in the field of diagnostic preparations; scientific laboratory services; custom design and development of biochemical assays; scientific and medical research laboratory services; research and development of new products for others; scientific research and analysis in the field of drug discovery; new product development in the field of pharmaceuticals for others; scientific advisory services, namely, medical advisory services related to pharmaceutical development and testing; scientific research consultancy in the field of cancer research, inflammatory disease research, auto-inflammatory disease research, autoimmune disease research, eye disease and disorder research, and intracellular delivery research of pharmaceuticals and therapeutics; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; consulting services for others in the field of design, planning, and implementation and project management of scientific research and clinical trials; providing scientific research information; technical advisory services relating to scientific and clinical research; provision of technical and scientific information and consultancy in relation to the aforesaid services

The mark consists of the wording "ELASMOGEN" with an irregular circular shape replacing the letter "O".

Trademark Events

Sep 29, 2023

New Application Office Supplied Data Entered

Sep 28, 2023

Sn Assigned For Sect 66a Appl From Ib

Jan 17, 2024

Assigned To Examiner

Jan 17, 2024

Non-Final Action Written

Oct 3, 2023

Application Filing Receipt Mailed

Jan 18, 2024

Non-Final Action (Ib Refusal) Prepared For Review

Feb 1, 2024

Refusal Processed By Mpu

Feb 19, 2024

Refusal Processed By Ib

Jul 29, 2024

Correspondence Received In Law Office

Jul 29, 2024

Teas/Email Correspondence Entered

Jul 29, 2024

Teas Response To Office Action Received

Jul 31, 2024

Approved For Pub - Principal Register

Aug 14, 2024

Notification Of Notice Of Publication E-Mailed

Sep 3, 2024

Published For Opposition

Sep 3, 2024

Official Gazette Publication Confirmation E-Mailed

Feb 1, 2024

Non-Final Action Mailed - Refusal Sent To Ib